Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases

BACKGROUND: People with autoimmune or inflammatory conditions taking immunomodulatory/suppressive medications may have higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. METHODS: We included parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Kathryn C, Mecoli, Christopher A, Douglas, Morgan, Harris, Samantha, Aravidis, Berna, Albayda, Jemima, Sotirchos, Elias S, Hoke, Ahmet, Orbai, Ana-Maria, Petri, Michelle, Christopher-Stine, Lisa, Baer, Alan N, Paik, Julie J, Adler, Brittany L, Tiniakou, Eleni, Timlin, Homa, Bhargava, Pavan, Newsome, Scott D, Venkatesan, Arun, Chaudhry, Vinay, Lloyd, Thomas E, Pardo, Carlos A, Stern, Barney J, Lazarev, Mark, Truta, Brindusa, Saidha, Shiv, Chen, Edward S, Sharp, Michelle, Gilotra, Nisha, Kasper, Edward K, Gelber, Allan C, Bingham, Clifton O, Shah, Ami A, Mowry, Ellen M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135997/
https://www.ncbi.nlm.nih.gov/pubmed/33956972
http://dx.doi.org/10.1093/cid/ciab407
Descripción
Sumario:BACKGROUND: People with autoimmune or inflammatory conditions taking immunomodulatory/suppressive medications may have higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. METHODS: We included participants with autoimmune or inflammatory conditions followed by specialists at Johns Hopkins. Participants completed periodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcare. We assessed whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterized pandemic-associated changes to care and mental health. RESULTS: In total, 265 (5.6%) developed COVID-19 over 9 months of follow-up (April–December 2020). Patient characteristics (age, race, comorbidity, medications) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in models incorporating behavior and other potential confounders (odds ratio [OR]: 1.43; 95% confidence interval [CI]: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95% CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95% CI: 1.24, 2.28), and kidney disease (OR: 1.76; 95% CI: 1.04, 2.97) were associated with higher odds of COVID-19. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions therein, which disproportionately affected individuals experiencing changes to employment or income. CONCLUSIONS: Glucocorticoid exposure may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions.

Ejemplares similares